Medical And Engineered Solutions Will Open New Markets

Key Takeaways

• Expansion into high-growth medical, electronics, and sustainable materials markets, supported by global capacity growth, is strengthening revenue prospects and operating margin outlook.
  
• Investments in automation and efficiency, alongside rising demand for innovative and eco-friendly solutions, are boosting margin potential and earnings quality.
  
• High CapEx for global expansion, overcapacity risks, and stagnating sales growth may constrain future margins and earnings, leaving Nolato vulnerable to market downturns.

Catalysts

Develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally.

• Accelerating global healthcare expenditure and an aging population are fueling Nolato's Medical Solutions growth, underpinned by expansion into high-volume and high-margin segments like drug delivery systems and in-vitro diagnostics, supporting sustained increases in revenue and probable upward pressure on operating margins.
  
• Rising electrification and connectivity trends-including wider adoption of 5G/6G and connected devices-are expanding demand for Nolato's advanced engineered solutions (e.g., EMC/antenna products), which, combined with Asian manufacturing expansion, creates opportunities for revenue growth and margin improvement as utilization increases.
  
• Heightened customer preference and regulatory focus on sustainability is driving greater demand for Nolato's innovative bio-based and recyclable polymer offerings, enhancing future revenue streams and potentially allowing for higher-margin product mixes.
  
• Ongoing investments in automation and operational efficiency (as evidenced by sequential margin improvement and targeted cost-outs) are reducing structural costs, directly supporting higher EBIT margins and improving overall earnings quality.
  
• Recent and ongoing global capacity expansions (Hungary, Malaysia, Poland) backed by secured contracts with major clients are laying the groundwork for multi-year organic revenue growth and improved earnings visibility, with CapEx investments likely to yield positive operating leverage as new facilities ramp up.

Nolato Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Nolato's revenue will grow by 7.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from 8.1% today to 9.4% in 3 years time.
• Analysts expect earnings to reach SEK 1.1 billion (and earnings per share of SEK 3.75) by about June 2029, up from SEK 759.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as SEK1.2 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 18.8x on those 2029 earnings, up from 16.8x today. This future PE is lower than the current PE for the GB Industrials industry at 26.7x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.74%, as per the Simply Wall St company report.

Risks

• High levels of CapEx related to global expansion (Hungary, Malaysia, Poland, and ongoing facility extensions) may not be fully offset by near-term revenue gains, leading to lower free cash flow and placing pressure on net margins and earnings if future demand is slower than anticipated.
  
• Overcapacity issues, particularly in China and the U.S. (notably within the GW Plastics acquisition), highlight ongoing risks of underutilization, which can suppress profitability and slow further margin expansion, potentially impacting group EBIT margins and earnings.
  
• Flat or single-digit organic sales growth (4%-5% even after currency adjustment) suggests the risk of growth stagnation as core markets, especially in Medical and Engineered Solutions, may reach saturation, which would limit revenue and long-term earnings growth.
  
• Ongoing margin improvement has been broad-based and driven by cost-outs, efficiency gains, and pricing; however, management acknowledges that further margin gains may be harder to achieve from current levels, potentially capping future net margin and earnings growth.
  
• Exposure to cyclical end-markets (Automotive, Consumer Electronics) and specific customer-driven expansions increases vulnerability to market downturns, contract losses, or slower adoption of new manufacturing sites, raising the risk of revenue volatility and margin compression.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of SEK63.67 for Nolato based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK11.5 billion, earnings will come to SEK1.1 billion, and it would be trading on a PE ratio of 18.8x, assuming you use a discount rate of 5.7%.
• Given the current share price of SEK47.4, the analyst price target of SEK63.67 is 25.5% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.